[1]贾中芝,顾晓诚,蒋国民.门静脉癌栓分型对肝细胞性肝癌治疗方法的选择及患者预后的影响 [J].介入放射学杂志,2017,(10):944-947.
 JIA Zhongzhi,GU Xiaocheng,JIANG Guomin.The application of portal vein tumor thrombus classification in selecting therapeutic method for HCC patients and in estimating the prognosis[J].journal interventional radiology,2017,(10):944-947.
点击复制

门静脉癌栓分型对肝细胞性肝癌治疗方法的选择及患者预后的影响 ()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年10期
页码:
944-947
栏目:
综述
出版日期:
2017-10-25

文章信息/Info

Title:
The application of portal vein tumor thrombus classification in selecting therapeutic method for HCC patients and in estimating the prognosis
作者:
贾中芝 顾晓诚 蒋国民
Author(s):
JIA Zhongzhi GU Xiaocheng JIANG Guomin
Department of Vascular Intervention, The Affiliated Changzhou Municipal No.2 People’s Hospital with Nanjing Medical University, Changzhou, Jiangsu Province 213003, China
关键词:
【关键词】 肝细胞肝癌 门静脉癌栓 分型 预后
文献标志码:
A
摘要:
【摘要】 门静脉癌栓(PVTT)是肝细胞性肝癌(HCC)患者常见的肿瘤晚期征象,预后差。目前,PVTT的分型方法有日本的VP分型和东方肝胆分型 (程氏分型),两者在PVTT分型方面有一定的区别。患者的预后与PVTT的类型存在相关性:Ⅰ0型PVTT患者预后最好,而Ⅳ型PVTT患者预后最差;不同类型的PVTT限制了治疗方式的选择,应根据PVTT的类型选择最佳的治疗方案,最大程度地控制肿瘤,使患者受益。

参考文献/References:

[1] Zhang ZM, Lai EC, Zhang C, et al. The strategies for treating primary hepatocellular carcinoma with portal ven tumor thrombus[J]. Int J Surg, 2015, 20: 8- 16.
[2] Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus[J]. World J Gastroen- terol, 2006, 12: 7561- 7567.
[3] Schoniger- Hekele M, Muller C, Kutilek M, et al. Hepatocellular carcinoma in Central Europe: prognostic features and survival[J]. Gut, 2001, 48: 103- 109.
[4] 程树群, 杨甲梅, 沈 锋, 等. 肝细胞癌合并门静脉癌栓多学科诊治——东方肝胆外科医院专家共识[J]. 中华肝胆外科杂志, 2015, 21: 582- 590.
[5] Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53: 1020- 1022.
[6] Jelic S, Sotiropoulos GC, ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up[J]. Ann Oncol, 2010, 21(Suppl 5): v59- v64.
[7] Yang M, Fang Z, Yan Z, et al. Transarterial chemoembo- lisation(TACE) combined with endovascular implantation of an iodine- 125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two- arm, randomised clinical trial[J]. J Cancer Res Clin Oncol, 2014, 140: 211- 219.
[8] Yu JI, Yoon SM, Park HC, et al. Multicenter validation study of a prognostic index for portal vein tumor thrombosis in hepatocellular carcinoma[J]. Cancer Res Treat, 2014, 46: 348- 357.
[9] Lu XJ, Dong J, Ji LJ, et al. Tolerability and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis[J]. Oncotarget, 2016, 7: 3614- 3622
[10] Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium- 90 microspheres: a comprehensive report of long- term outcomes[J]. Gastroenterology, 2010, 138: 52- 64.
[11] Zhang YQ, Fan WZ, Wang Y, et al. Sorafenib with and without transarterial chemoembolization for advanced hepatocellular carcinoma with main portal vein tumor thrombosis: a retrospective analysis[J]. Oncologist, 2015, 20: 1417- 1424.
[12] Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus[J]. Surg Today, 2014, 44: 219- 226.
[13] European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL- EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56: 908- 943.
[14] Omata M, Lesmana LA, Tateishi R, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma[J]. Hepatol Int, 2010, 4: 439- 474.
[15] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J]. 临床肝胆病杂志, 2011, 27: 1141- 1159.
[16] Tsai AL, Burke CT, Kennedy AS, et al. Use of yttrium- 90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis[J]. J Vasc Interv Radiol, 2010, 21: 1377- 1384.
[17] No authors listed. The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan[J]. Jpn J Surg, 1989, 19: 98- 129.
[18] Shuqun C, Mengchao W, Han C, et al. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein[J]. Hepatogastroenterology, 2007, 54: 499- 502.
[19] 全国肝癌合并癌栓诊治研究协作组.肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2016年版)[J]. 消化肿瘤杂志·电子版, 2016, 8: 130- 135.
[20] Li W, Dai Z, Yao L, et al. Chemoembolization and stenting combined with iodine- 125 seed strands for the treatment of hepatocellular carcinoma with inferior vena cava obstruction[J]. Exp Ther Med, 2015, 10: 973- 977.
[21] Zhang W, Yan Z, Luo J, et al. Iodine- 125 seeds strand for treatment of tumor thrombus in inferior vena cava: an experimental study in a rabbit model[J]. Cardiovasc Intervent Radiol, 2013, 36: 1371- 1382.
[22] 伍 路, 杨业发, 申淑群, 等. 门静脉癌栓微波消融及射频消融治疗80例分析[J]. 介入放射学杂志, 2016, 25: 510- 514.
[23] 樊 嘉, 汤钊猷, 吴志全, 等. 门静脉微癌栓和肉眼癌栓对肝癌患者术后生存的影响[J]. 中华外科杂志, 2005, 43: 433- 435.
[24] Shi J, Lai EH, Li N, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2010, 17: 2073- 2080.
[25] Niu ZJ, Ma YL, Kang P, et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification[J]. Med Oncol, 2012, 29: 2992- 2997.
[26] Kokudo N, Hasegawa K, Akahane M, et al. Evidence- based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update(3rd JSH- HCC Guidelines)[J]. Hepatol Res, 2015, 45: doi10.1111/hepr.12464.
[27] Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study[J]. Ann Surg Oncol, 2011, 18: 413- 420.
[28] Zhu K, Chen J, Lai L, et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib: a retrospective controlled study[J]. Radiology, 2014, 272: 284- 293.
[29] 程树群, 吴孟超, 陈 汉, 等. 癌栓分型对肝细胞性肝癌合并门静脉癌栓治疗及预后的指导意义[J]. 中华医学杂志, 2004, 84: 3- 5.
[30] 王海梁, 丁国善, 郭闻渊, 等. 癌栓分型对肝癌伴门静脉癌栓病人肝移植术预后的指导意义[J]. 中华肝胆外科杂志, 2009, 15: 745- 747.

相似文献/References:

[1].关于召开“全国肝癌介入治疗研讨会”的通知[J].介入放射学杂志,1995,(04):200.
[2]张   磊,陆骊工,李   勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
 ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(10):968.
[3]李海伟,刘 静,李 森.125I粒子植入与伽玛刀治疗门脉癌栓的疗效对比[J].介入放射学杂志,2014,(08):702.
 LI Hai wei,LIU Jing,LI Sen..125Iodine seed implantation and gamma knife for the treatment of portal vein tumor thrombosis in hepatocellular carcinoma: comparison of therapeutic efficacy[J].journal interventional radiology,2014,(10):702.
[4]杨柏帅,施裕新,袁 敏,等.TACE治疗既往有肝功能衰竭史肝癌患者七例[J].介入放射学杂志,2014,(09):805.
 YANG Bo shuai,SHI Yu xin,YUAN Min,et al.TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history: initial experience in seven cases[J].journal interventional radiology,2014,(10):805.
[5]刘 岩,刘瑞宝,王 平,等. 经导管植入125I放射性粒子治疗肝癌伴门静脉癌栓19例[J].介入放射学杂志,2014,(01):35.
 LIU Yan,LIU Rui? bao,WANG Ping,et al. Percutaneous transcatheter implantation of 125iodine seeds for the treatment of liver cancer associated with portal vein tumor thrombus: initial experience in 19 cases[J].journal interventional radiology,2014,(10):35.
[6]贾 佳,祁兴顺,韩国宏. 肝动脉化疗栓塞在肝细胞肝癌合并门静脉癌栓患者中的应用[J].介入放射学杂志,2014,(04):352.
 JIA Jia,QI Xing-Shun,HAN Guo-hong.. Application of transarterial chemoembolization in treating hepatocellular carcinoma associated with portal vein tumor thrombus[J].journal interventional radiology,2014,(10):352.
[7]任海涛,李任飞,王月东. 原发性肝癌合并门静脉癌栓的治疗进展[J].介入放射学杂志,2013,(11):965.
 REN Hai? tao,LI Ren? fei,WANG Yue? dong.. Recent advances in the treatment of hepatocellular carcinoma with portal vein tumor thrombus[J].journal interventional radiology,2013,(10):965.
[8]邢桃红,牛焕章,周媛媛,等. TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志,2014,(05):449.
 XING Tao- hong,NIU Huan- zhang,ZHOU Yuan- yuan,et al. Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib: initial experience in 23 cases[J].journal interventional radiology,2014,(10):449.
[9]阿布都外力·吾布力卡斯穆,迪里木拉提·巴吾冬,任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J].介入放射学杂志,2014,(05):435.
 ABUDUWAILI Obulikasimu,DILMURAT Bawudun,REN Wei- xin.. Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma: analysis of the prognosis and survival[J].journal interventional radiology,2014,(10):435.
[10]尹立楠,刘 岩,刘瑞宝.经导管植入放射性125I粒子治疗门静脉癌栓1例[J].介入放射学杂志,2015,(04):295.
 YIN Li nan,LIU Yan,LIU Rui bao.Transcatheter implantation of 125I seeds for the treatment of portal vein tumor thrombus: report of one case[J].journal interventional radiology,2015,(10):295.
[11]王 龙,张 勇,王亚运,等.125I粒子联合经导管动脉化疗栓塞治疗肝细胞肝癌伴门静脉癌栓临床有效性与安全性meta 分析[J].介入放射学杂志,2018,27(05):419.
 WANG Long,ZHANG Yong,WANG Yayun,et al.125I seed implantation combined with TACE for the treatment of HCC complicated by portal vein tumor thrombus: a meta- analysis of its clinical effectiveness and safety[J].journal interventional radiology,2018,27(10):419.

备注/Memo

备注/Memo:
(收稿日期:2016-05-19)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2017-10-15